What is CDNA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 3.29B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CDNA?

P/E (TTM) is 29.67 and 52-week range is $13.95 to $72.51 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CDNA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CDNA?

The company profile lists revenue (TTM) near $443M, net income (TTM) near $107M, EPS (TTM) near $2.07 when available from the market-data feed. Figures are informational and may lag live markets.

Where is CareDx Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Brisbane California, California, US, 51.7M shares outstanding, ISIN US14167L1035 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

CareDx Inc

$CDNA

Health Care · Biotechnology

IR Run Scenarios

$63.67

+2.36%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. The company is headquartered in Brisbane California, California and currently employs 761 full-time employees. The company went IPO on 2014-07-17. The firm is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. The company offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. The company also offers a diverse portfolio of digital solutions to transplant centers.

Employees

761

Website

www.caredx.com/

IPO

2014-07-17

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)